Haerbin Taihua Pharmaceutical Co. Ltd.

Primary study objective: To investigate the in vivo pharmacokinetic characteristics of the test preparation ibuprofen tablets (specification: 0.2 g, developed by Harbin Taihua Pharmaceutical Co., Ltd.) and the reference preparation ibuprofen tablets (trade name: Motrin IB ®, specification: 0.2 g, licensed by Johnson and Johnson Consumer Inc McNeil Consumer Healthcare Division) after a single oral administration of the test preparation ibuprofen tablets (specification: 0.2 g, developed by Harbin Taihua Pharmaceutical Co., Ltd.) in Chinese health research participants under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary study objective: To evaluate the safety of a single oral administration of 0.2 g of the test preparation and the reference preparation of ibuprofen tablets in Chinese health research participants.